

EVALUATION OF A DERMOCOSMETIC IN THE MANAGEMENT OF ROSACEA-PRONE SKIN

S. SEITE

La Roche-Posay Dermatological Laboratories, Asnières, France

INTRODUCTION


Rosacea is a chronic skin disease which requires long-term therapy. Due to the high risk of relapse, continued topical use is recommended as maintenance therapy. A vital point in the treatment is patient education including verbal and written information about rosacea concerning psychological aspects, flare factors (alcohol, stress, spicy food...), skin care, make-up... which help to counteract negative self-image and improved patient quality of life.

METHODS



Several studies were performed in order to evaluate the efficacy as monotherapy or in association with or follow-up to other treatments of a dermocosmetic containing Ambophenol, Neurosensine and La Roche-Posay thermal spring water formulated in a highly protective packaging. A first study was performed on 37 women aged 18-45 with erythrocouperosis (stage ≥ 2), who applied the tested formula twice a day for 4 weeks. The investigating dermatologist clinically evaluated the redness and telangiectasia at T4 weeks, and then 1 week after stopping the treatment (T5 weeks). Intensity of redness and telangiectasia were evaluated using a visual analog scale (VAS) ranging from 0 (no symptoms) to 9 (intense symptoms). During a second study performed on 117 patients (20% M and 80% F) aged 20-80 with stage I rosacea, a questionnaire containing information about patients' characteristics, tolerance, clinical signs, symptoms and skin reactivity to trigger factors was completed by dermatologists at baseline and 2 months after treatment with the tested formula alone. In a third study, 65 patients finishing an 8-week Metronidazole treatment applied once daily (evening) were divided into 2 groups using the tested formula or its vehicle twice a day for 8 weeks for the evaluation of its efficacy as adjunctive therapy.

RESULTS

1. Evaluation of efficacy on redness in monotherapy




A significant efficacy as monotherapy associated with an excellent tolerance was noticed after a 1 month's use on erythrocouperotic skin. This efficacy was prolonged even 1 week after stopping the treatment (T5 weeks).



2. Impact on clinical signs, symptoms and triggering factors in monotherapy

In the second study, there was a significant improvement of all the clinical signs and symptoms (Reduction of -38%) and a significant reduction of the skin reactivity to trigger factors (-38%) of patients with a stage I rosacea (n=117). In addition, the tolerance and the satisfaction to the tested formula were good to excellent in 85% and 74% of cases respectively and in 77% of cases patients noticed a good impact on their skin quality.




	V1	V2	%
Score of signs and symptoms	9,83 ± 4,04	6,12 ± 3,67*	-38%
Score of trigger factors	13,38 ± 6,21	10,77 ± 6,10*	-38%

*p<0,05 versus V1

3. Evaluation of the efficacy post-prescription treatment

The tested formula was also evaluated in association with a leading rosacea prescription. After stopping a 8 weeks treatment with Metronidazole, the percentage of patients with global improvement in the signs of rosacea stayed significantly higher in the group treated with the tested formula compared to the one treated with the vehicle. A dermocosmetic containing Ambophenol, Neurosensine and La Roche-Posay thermal spring water in a highly protective packaging helps prolong the efficacy of a Metronidazole treatment.



CONCLUSION

All these studies highlight the interest of a dermocosmetic containing Ambophenol, Neurosensine and La Roche-Posay thermal spring water formulated in a highly protective packaging in monotherapy or in combination with or after a therapeutic treatment in the management of patients suffering from rosacea.